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Abstract
Diarrhea is the second leading cause of death of children under 5 worldwide. 
Standard treatment is administration of an oral rehydration solution (ORS), with 
zinc supplementation in developing countries. Recent studies propose addition of 
probiotic supplementation to this established standard. This research examines 
the efficacy of probiotic supplementation in reducing diarrhea duration when 
compared to traditional treatment of oral rehydration in healthy pediatric 
patients (under 5 years old, with no chronic conditions) with acute diarrhea.
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Diarrhea: 3 or more loose watery stools per day 
➢ 2nd leading cause of death in children under 5 years old  
➢ 70,000 pediatric hospitalizations in the US yearly  
➢ 1.7 million Emergency Department visits each year in the US  
Standard treatment: Oral rehydration solution (ORS) 
➢ Zinc supplementation added to ORS in developing countries  
Probiotics: live organisms that can provide health benefits when ingested 
➢ Increasingly recommended for various gastrointestinal complaints as research 
into the human gut microbiome continues to develop  
➢ Rapidly growing industry, projected worth of $69.3 billion by 2023
Introduction
Methods
A literature search was performed using PubMed and ScienceDirect databases in 
November 2019. Please see Figures 1 and 2 for details.  
Of the 11 studies selected in this process, 6 were chosen for analysis: 
• Excluded studies suffered from small sample sizes, weak treatment design, 
limited reporting of results, or significant presence of bias. 
• Studies for analysis were chosen for relevancy to the research topic, as well as 
similarities in study design, exclusion criteria, and outcome measures.  
2 studies do not support probiotic use  
Freedman, et al and Schnadower, et al  
• The 2 largest studies analyzed (n = 827, 943) 
• Strains utilized:  Lactobacillus rhamnosus R001 + 
Lactobacillus helveticus R0052 , Lactobacillus rhamnosus GG 
• Neither found any SS or CS improvement with probiotic use 
• 1 study reported increased adverse events in probiotic group  
• More robust study design:  
          - Only studies using Modified Vesikari score as an outcome         
            measure, an objective tool to grade gastroenteritis severity  
          - Only studies with precautions in place for missed dose 
4 studies support probiotic use 
Das, et al; Dinleyici, et al; Maragkoudaki, et al; Sudha, et al 
• Smaller sample sizes (n = 51, 58, 119, 127)  
• Strains utilized: Lactobacillus reuteri DSM 17938 (2 studies), Bacillus 
clausii UBBC-07, Saccharomyces boulardii  
• 3 found SS reduction of diarrhea duration 
• Less robust study design: 
        - More subjective outcome measures  
        - Less detailed procedures  
        - Increased potential for bias: 3 studies reported connections   
           to pharmaceutical companies producing probiotics 
Differences in study design makes comparison difficult 
• Variation in probiotic strains used 
• Differences in exclusion criteria used by researchers  
• Geographic diversity: gut microbiota can vary between  countries due 
to differences in diet, hygiene, and breastfeeding 
Discussion 
Results 
Probiotic Supplementation in Acute Pediatric Diarrhea
Despite recent increased interest in probiotics, no consensus has been 
reached on their efficacy in regards to pediatric diarrhea treatment. In 
addition to the conflicting findings summarized in this poster,  experts are 
split in their recommendations. Both the CDC and National Institute for 
Health and Care excellence do not recommend the use of probiotics in this 
context, while the European Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition strongly recommends this treatment. 
Further study is warranted, with stricter protocol on larger scales. Studies 
comparing multiple probiotic strains to placebo would lend valuable 
information to this field.  
Given the conflicting results demonstrated in this research, no 
recommendation can be made at this time in favor of probiotic use in the 
treatment of acute pediatric diarrhea.
Conclusion
Das, et al: Double-blind RCT (n = 58.) Statistically significant (SS) reductions in 
diarrhea duration and hospitalization duration in children treated with 
Saccharomyces boulardii as inpatients in India.  
Dinleyici, et al: Single-blind RCT (n = 127.) SS reductions in diarrhea duration, 
frequency, and hospitalization duration in children treated with Lactobacillus 
reuteri DSM 17938 as inpatients in Turkey.    
Freedman, et al: Double-blind RCT (n = 827.) No SS or clinically significant (CS) 
improvement in diarrhea duration, diarrhea frequency, modified Vesikari 
score, or daycare absences in children treated with Lactobacillus rhamnosus 
R001 + Lactobacillus helveticus R0052 as outpatients in Canada.   
Maragkoudaki, et al: Double-blind RCT (n = 51.) No SS improvement in 
diarrhea duration, diarrhea frequency, or daycare absences; authors note 
clinical improvement in all 3 of these areas in children treated with 
Lactobacillus reuteri DSM 17938 + zinc as outpatients in Greece.  
Schnadower, et al: Double-blind RCT (n = 943.) No SS or CS improvement in 
diarrhea duration, diarrhea frequency, modified Vesikari score, or daycare 
absences in children treated with Lactobacillus rhamnosus GG as outpatients 
in the United States.  
5 children (0.01%) in treatment group experienced wheezing. 
0 children in control group experienced wheezing.  
Sudha, et al: Double-blind RCT (n = 119.) SS improvement of diarrhea 
duration, no SS improvement of diarrhea frequency in children treated with  
Bacillus clausii UBBC-07 as outpatients in India. 
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